China Touyun Tech Group (1332) AI Stock Analysis

• Market Cap: HK$283.40M
• Dividend Yield: N/A
• Average Volume (3M): 780.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: -30.86%
• EPS Growth: 87.59%
• Country: HK
• Employees: 485
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Packaging & Containers
• EPS (TTM): <0.01
• Shares Outstanding: 2,805,952,100
• 10 Day Avg. Volume: 1,798,062
• 30 Day Avg. Volume: 780,552
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by negative profitability and a strained balance sheet. Technical analysis shows some short-term positive momentum, but the long-term outlook remains bearish. Valuation metrics are unattractive due to negative earnings and the absence of dividends.

China Touyun Tech Group Business Overview & Revenue Model

Company Description

Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People's Republic of China, Europe, North and South America, and internationally. It operates through four segments: QR Code Business, Packaging Products, Treasury Investment, and Chlamydomonas Reinhardtii Product Business. The QR Code Business segment provides QR codes on product packaging and solutions, and advertising display services. The Packaging Products segment manufactures and sells watch and jewelry boxes, eyewear cases, bags and pouches, and display units. The Treasury Investment segment invests and trades in securities, as well as offers money lending, placing and underwriting, securities brokerage, asset management, and margin financing services. The Chlamydomonas Reinhardtii Product Business segment produces and sells chlamydomonas reinhardtii, micro-algae, and related products. It also provides business intelligence IT solutions, online advertising display, and corporate management services. The company was formerly known as China Touyun Tech Group Limited and changed its name to Touyun Biotech Group Limited in May 2021. Touyun Biotech Group Limited was founded in 1989 and is headquartered in Wan Chai, Hong Kong.

How the Company Makes Money

China Touyun Tech Group generates revenue through a diversified business model that includes the sale of physical packaging products as well as digital technology services. The company sells smart packaging solutions to various industries, leveraging technology to provide added value such as anti-counterfeiting measures and traceability features. Additionally, it earns income from digital platform services aimed at supporting businesses in improving their supply chain and operational efficiencies. Strategic partnerships with technology firms and consumer goods companies also play a significant role in expanding its market reach and enhancing its product offerings.

China Touyun Tech Group Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues, negative profitability, and a strained balance sheet. Negative equity and high leverage pose substantial risks, while cash flow constraints limit strategic options.

Income Statement

The income statement reflects a challenging financial position with declining revenues and negative profit margins. The gross profit margin is positive but has deteriorated over time, indicating rising costs or pricing pressures. EBIT and EBITDA margins are negative, suggesting operational inefficiencies or high fixed costs. Net income remains negative, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet shows significant financial stress with negative stockholders' equity, indicating insolvency. The debt-to-equity ratio is not meaningful due to negative equity, but total debt is substantial compared to assets. Despite a decrease in total assets, liabilities have increased, further weakening the financial position. The equity ratio is negative, emphasizing the company's reliance on debt financing.

Cash Flow

Cash flow analysis reveals weak operational cash generation with zero operating cash flow in the latest period. Free cash flow has been negative, indicating cash burn and insufficient cash flow to cover capital expenditures. The absence of recent positive cash flow metrics limits financial flexibility and investment capacity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	159.97M	198.64M	315.82M	283.50M	206.79M
Gross Profit	72.07M	56.60M	120.12M	107.05M	84.61M
EBITDA	-27.92M	-228.57M	-144.39M	-83.13M	-87.22M
Net Income	-88.11M	-268.94M	-198.06M	-72.95M	-171.99M
Balance Sheet
Total Assets	550.32M	607.34M	887.70M	1.02B	971.94M
Cash, Cash Equivalents and Short-Term Investments	69.64M	36.04M	144.25M	93.95M	254.40M
Total Debt	384.59M	384.91M	395.01M	317.37M	222.62M
Total Liabilities	590.96M	586.27M	604.19M	537.68M	415.57M
Stockholders Equity	-83.20M	-848.00K	263.96M	469.92M	488.04M
Cash Flow
Free Cash Flow	-53.54M	-13.49M	-39.30M	-304.60M	-140.86M
Operating Cash Flow	-49.87M	3.65M	-26.37M	-53.81M	-15.35M
Investing Cash Flow	-4.66M	-70.95M	-17.25M	-147.74M	-47.87M
Financing Cash Flow	35.74M	-27.68M	102.63M	123.17M	160.47M

China Touyun Tech Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Neutral. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.93 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1332.

China Touyun Tech Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6898	64 Neutral	726.92M	45.56	0.00%	0.56%	-2.08%	-23.18%
1626	54 Neutral	1.60B	-145.11	11.24%	―	-82.87%	-110.99%
8291	48 Neutral	16.00M	3.62	7.43%	―	-44.08%	0.00%
1332	47 Neutral	HK$283.40M	―	-335.55%	―	-30.86%	87.59%
1820	46 Neutral	796.67M	-37.91	-3.68%	3.00%	4.56%	-186.08%
0252	45 Neutral	360.67M	-14.11	-2.29%	1.87%	20.54%	-145.32%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%

China Touyun Tech Group Corporate Events

Touyun Biotech Group Reports Turnaround in Interim Results

Touyun Biotech Group Limited reported its unaudited interim results for the six months ending June 30, 2025, showing a significant turnaround with a profit of HK$28.05 million compared to a loss of HK$48.82 million in the same period in 2024. This improvement was driven by gains in other income and a reduction in losses from discontinued operations, positioning the company more favorably in its market.

Touyun Biotech Schedules Board Meeting for Interim Results and Dividend Decision

Touyun Biotech Group Limited has announced a board meeting scheduled for August 22, 2025, to approve the interim financial results for the first half of the year and discuss the potential payment of an interim dividend. This meeting is significant as it may impact the company’s financial strategy and shareholder returns, reflecting its operational performance and future financial planning.

Touyun Biotech Group Announces Disposal of Steam Pipeline Assets

Touyun Biotech Group Limited has entered into an agreement to dispose of certain steam pipeline facilities in Shanxi for RMB14,816,964. This transaction, classified as discloseable, is expected to streamline operations and potentially impact the company’s financials by reallocating resources from non-core assets.

Touyun Biotech Group Announces Board Composition and Roles

Touyun Biotech Group Limited has announced the composition of its board of directors along with the roles and functions of each member. The announcement details the executive, non-executive, and independent non-executive directors, as well as the membership of the audit, nomination, and remuneration committees. This update provides clarity on the governance structure of the company, which can impact its strategic direction and stakeholder confidence.

Touyun Biotech Announces Changes in Nomination Committee Leadership

Touyun Biotech Group Limited, a company incorporated in Bermuda, has announced a change in the composition of its Nomination Committee. Mr. Cheung Wing Ping, previously a member of the committee, has been appointed as its chairman, replacing Mr. Wang Liang. These changes, effective from July 4, 2025, aim to bring new leadership to the committee, potentially impacting the company’s governance and strategic direction.

Touyun Biotech Group Implements Strategic Measures to Enhance Financial Stability

Touyun Biotech Group Limited has announced a series of strategic measures to address its liquidity challenges and improve its financial position, as outlined in its 2024 Annual Report. The company is actively launching new health products to expand its market presence and has secured financial support through loans and shareholder agreements to defer debt repayments. Additionally, the company is exploring the sale of non-core assets to bolster working capital, with recent disposals expected to yield significant gains.

China Touyun Tech Group Updates Nomination Committee Terms

China Touyun Tech Group has revised the terms of reference for its Nomination Committee, which is responsible for appointing and managing directors. The committee will consist of at least three members, with a majority being independent non-executive directors, and meetings will be held at least once a year. This move is likely aimed at strengthening governance and ensuring diverse representation within the company’s leadership structure.

Touyun Biotech Group Confirms AGM and SGM Results

Touyun Biotech Group Limited, a company incorporated in Bermuda, announced the results of its Annual General Meeting (AGM) and Special General Meeting (SGM) held on June 13, 2025. The announcement clarified that no participants indicated an intention to abstain from or oppose any resolutions during these meetings. This supplemental information ensures transparency and confirms that all previously disclosed details remain unchanged.

Touyun Biotech Approves Major Disposal Agreement

Touyun Biotech Group Limited held a Special General Meeting on June 13, 2025, where a resolution was passed to approve the Disposal Agreement. This agreement involves the sale of 70% of the shares of a target company for RMB13,000,000. The resolution was overwhelmingly supported, with 99.99% of votes in favor, indicating strong shareholder backing for the transaction.

Touyun Biotech Group Limited Announces Board Composition and Committee Roles

Touyun Biotech Group Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The company has also detailed the membership of its three board committees: Audit, Nomination, and Remuneration, highlighting the roles of each director within these committees. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the leadership dynamics and decision-making processes within Touyun Biotech Group Limited.